Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in the Diagnosis and Treatment of Venous Thromboembolism
share announcement

Advances in the Diagnosis and Treatment of Venous Thromboembolism

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (20 April 2022) | Viewed by 7107

Special Issue Editor

Dr. Karsten Keller

E-Mail Website
Guest Editor
Department of Cardiology (Cardiology I), University Medical Center, Johannes Gutenberg Universität Mainz, Mainz, Germany
Interests: venous thromboembolism; pulmonary embolism; risk factors; risk stratification; hemostasis; thrombosis; myocardial infarction

Special Issue Information

Dear Colleagues,

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism (PE), is a commonly diagnosed condition with significant morbidity and mortality. In particular, PE is a life-threatening VTE manifestation, and it is of outstanding importance to establish the diagnosis in a timely manner. Nevertheless, the clinical presentation of acute PE patients comprises a wide spectrum, from asymptomatic patients to unspecific as well as typical symptoms, and it can be challenging to quickly establish the correct diagnosis. Additionally, a risk stratification of these patients is crucial to identify those who will benefit from more aggressive treatment strategies. These challenging aspects regarding VTE diagnosis, risk stratification and treatment, in light of medical progress, should be the aims of this Special Issue. Beyond specialists from cardiology and vascular medicine, researchers with a focus on imaging, inflammation or other affiliated disciplines are also invited to submit original articles or reviews to enhance the knowledge in VTE research.

Dr. Karsten Keller
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • venous thromboembolism
  • pulmonary embolism
  • deep venous thrombosis
  • risk stratification
  • thrombosis
  • VTE risk factors
  • anticoagulation

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 775 KiB  
Article
Thrombophilia Impact on Treatment Decisions, Subsequent Venous or Arterial Thrombosis and Pregnancy-Related Morbidity: A Retrospective Single-Center Cohort Study
by Kristina Vrotniakaite-Bajerciene, Tobias Tritschler, Katarzyna Aleksandra Jalowiec, Helen Broughton, Justine Brodard, Naomi Azur Porret, Alan Haynes, Alicia Rovo, Johanna Anna Kremer Hovinga, Drahomir Aujesky and Anne Angelillo-Scherrer
J. Clin. Med. 2022, 11(14), 4188; https://doi.org/10.3390/jcm11144188 - 19 Jul 2022
Cited by 4 | Viewed by 1862
Abstract
(1) Background: Thrombophilia testing utility has remained controversial since its clinical introduction, because data on its influence on treatment decisions are limited. (2) Methods: We conducted a single-center retrospective cohort study of 3550 unselected patients referred for thrombophilia consultation at the Bern University [...] Read more.
(1) Background: Thrombophilia testing utility has remained controversial since its clinical introduction, because data on its influence on treatment decisions are limited. (2) Methods: We conducted a single-center retrospective cohort study of 3550 unselected patients referred for thrombophilia consultation at the Bern University Hospital in Switzerland from January 2010 to October 2020. We studied the influence of thrombophilia testing results on treatment decisions and evaluated the association between thrombophilia and thromboembolic and pregnancy-related morbidity events after testing up to 03/2021. (3) Results: In 1192/3550 patients (34%), at least one case of thrombophilia was found and 366 (10%) had high-risk thrombophilia. A total of 211/3550 (6%) work-ups (111/826 (13%) with low-risk thrombophilia and 100/366 (27%) with high-risk thrombophilia) led to an appropriate decision to extend or initiate anticoagulation, and 189 (5%) negative results led to the withholding of anticoagulation therapy inappropriately. A total of 2492 patients (69%) were followed up for >30 days, with a median follow-up of 49 months (range, 1–183 months). Patients with high-risk thrombophilia had a higher risk of subsequent venous thromboembolic events and pregnancy-related morbidity compared to those without thrombophilia. (4) Conclusions: Our study demonstrated the limited usefulness of thrombophilia work-up in clinical decision-making. High-risk thrombophilia was associated with subsequent venous thromboembolism and pregnancy-related morbidity. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Venous Thromboembolism)
►▼ Show Figures

Figure 1

10 pages, 245 KiB  
Article
Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants—A Retrospective Cohort Study
by Irit Ayalon-Dangur, Yakov Vega, Miriam Rozi Israel, Alon Grossman, Galia Spectre, Tzippy Shochat, Leonard Leibovici and Anat Gafter-Gvili
J. Clin. Med. 2021, 10(23), 5673; https://doi.org/10.3390/jcm10235673 - 1 Dec 2021
Cited by 4 | Viewed by 2536
Abstract
Introduction: Randomized controlled trials that compared direct oral anticoagulants (DOACs) to vitamin K antagonists (VKA) for the treatment of venous thromboembolism (VTE), demonstrated both efficacy and safety of DOACs. The aim of the current study was to compare DOACs to VKA for the [...] Read more.
Introduction: Randomized controlled trials that compared direct oral anticoagulants (DOACs) to vitamin K antagonists (VKA) for the treatment of venous thromboembolism (VTE), demonstrated both efficacy and safety of DOACs. The aim of the current study was to compare DOACs to VKA for the treatment of VTE in the elderly, in a real-life setting. Methods: A retrospective cohort study was performed in Rabin Medical Center encompassing a 7-year period. Hospitalized patients >65 years, with a diagnosis of VTE discharged with DOACs or VKA were included. The primary outcome was a composite of all-cause mortality, major bleeding, recurrent VTEs and hospitalizations throughout the follow-up period of one year. Results: A total of 603 patients were included in the final analysis. The mean age was 79.6 ± 8.5 years. The primary composite outcome occurred in 74.6% and 56.7% of the patients in the VKA group and DOACs group, respectively, hazard ratio 0.59, 95% confidence interval 0.46 to 0.76, in favor of the DOACs group. In a matched cohort analysis, the results were the same as the original analysis. Conclusion: In the elderly population, treatment of VTE with DOACs was associated with a lower rate of the composite outcome. DOACs are safe and effective for elderly patients with VTE. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Venous Thromboembolism)
►▼ Show Figures

Graphical abstract

14 pages, 778 KiB  
Article
Risk Factors for Pulmonary Embolism in Patients with Paralysis and Deep Venous Thrombosis
by Karsten Keller, Jens Wöllner, Volker H. Schmitt, Mir A. Ostad, Ingo Sagoschen, Thomas Münzel, Christine Espinola-Klein and Lukas Hobohm
J. Clin. Med. 2021, 10(22), 5412; https://doi.org/10.3390/jcm10225412 - 19 Nov 2021
Cited by 4 | Viewed by 2323
Abstract
Background. Venous thromboembolism is a frequent complication and an important cause of death in patients with paralysis. We aimed to investigate predictors of pulmonary embolism (PE) and the impact of PE on the survival of patients with paralysis in comparison to those with [...] Read more.
Background. Venous thromboembolism is a frequent complication and an important cause of death in patients with paralysis. We aimed to investigate predictors of pulmonary embolism (PE) and the impact of PE on the survival of patients with paralysis in comparison to those with deep venous thrombosis or thrombophlebitis (DVT). Methods: Patients were selected by screening the German nationwide inpatient sample (2005–2017) for paralysis, and were stratified for venous thromboembolism (VTE) and the VTE-sub-entity PE (ICD-code I26). Impact of PE on mortality and predictors for PE were analyzed. Results: Overall, 7,873,769 hospitalizations of patients with paralysis were recorded in Germany 2005–2017, of whom 1.6% had VTE and 7.0% died. While annual hospitalizations increased (2005: 520,357 to 2017: 663,998) (β 12,421 (95% CI 10,807 to 14,034), p < 0.001), in-hospital mortality decreased from 7.5% to 6.7% (β −0.08% (95% CI −0.10% to −0.06%), p < 0.001). When focusing on 82,558 patients with paralysis hospitalized due to VTE (51.8% females; 58.3% aged ≥ 70 years) in 2005–2017, in-hospital mortality was significantly higher in patients with paralysis and PE than in those with DVT only (23.8% vs. 6.3%, p < 0.001). Cancer (OR 2.18 (95% CI 2.09–2.27), p < 0.001), heart failure (OR 1.83 (95% CI 1.76–1.91), p < 0.001), COPD (OR 1.63 (95% CI 1.53–1.72), p < 0.001) and obesity (OR 1.42 (95% CI 1.35–1.50), p < 0.001) were associated with PE. PE (OR 4.28 (95% CI 4.07–4.50), p < 0.001) was a strong predictor of in-hospital mortality. Conclusions: In Germany, annual hospitalizations of patients with paralysis increased in 2005–2017, in whom VTE and especially PE substantially affected in-hospital mortality. Cancer, heart failure, COPD, obesity and acute paraplegia were risk factors of PE. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Venous Thromboembolism)
►▼ Show Figures

Figure 1

Other

Jump to: Research

13 pages, 3742 KiB  
Systematic Review
Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
by Ikhwan Rinaldi, Ihya Fakhrurizal Amin, Yuli Maulidiya Shufiyani, Idham Rafly Dewantara, Brenda Cristie Edina, Kevin Winston and Yusuf Aji Samudera Nurrobi
J. Clin. Med. 2022, 11(14), 4070; https://doi.org/10.3390/jcm11144070 - 14 Jul 2022
Cited by 3 | Viewed by 2317
Abstract
Venous thromboembolism (VTE) is a serious complication that can occur during and after postoperative treatment, including in treatment after orthopedic surgery. The current guidelines for VTE prophylaxis in postoperative patients recommend the use of LMWHs, one of which is enoxaparin. Another recommendation for [...] Read more.
Venous thromboembolism (VTE) is a serious complication that can occur during and after postoperative treatment, including in treatment after orthopedic surgery. The current guidelines for VTE prophylaxis in postoperative patients recommend the use of LMWHs, one of which is enoxaparin. Another recommendation for use in pharmacological VTE prophylaxis is rivaroxaban, which has better efficacy than enoxaparin but a higher bleeding risk. The aim of this systematic review is to provide an update on the profile of rivaroxaban for VTE prophylaxis after orthopedic surgery. PubMed, SCOPUS, EMBASE, and EBSCOhost were searched up until May 2022. The outcome sought was efficacy and safety, described by the incidence of VTE and incidence of bleeding, respectively. Five randomized controlled trials (RCT) were finally included. Rivaroxaban was confirmed to have better efficacy by significantly reducing the risk of VTE and all-cause mortality (RR = 0.38; 95% CI = 0.27–0.54) compared to enoxaparin. However, regarding the safety variable, no significant difference was found between the incidence of major bleeding in rivaroxaban and enoxaparin (RR = 0.97; 95% CI = 0.56–1.68). The results of the analysis show that rivaroxaban has better efficacy than enoxaparin but the same safety profile, so when used, the bleeding of patients should still be monitored. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Venous Thromboembolism)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop